Efficacy and safety of iguratimod in patients with primary Sjögren’s syndrome: a multicentre randomised controlled trial
Xiaochan Chen, Ting Zhang, Lifeng Meng, Cheng Xu, Lichun Jiang, Guofang Wang, Tao Hou, Hongzhi Wang, Yongmei Han, Ying Guan, Yingying Wang, Jing Xue · 2025
Read Efficacy and safety of iguratimod in patients with primary Sjögren’s syndrome: a multicentre randomised controlled trial by Xiaochan Chen, Ting Zhang, Lifeng Meng, Cheng Xu, Lichun Jiang, Guofang Wang, Tao Hou, Hongzhi Wang, Yongmei Han, Ying Guan, Yingying Wang, Jing Xue (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12718576.txt.
Description
Xiaochan Chen and co-authors report a 2025 trial of a drug for primary Sjogren's syndrome, a disease that dries the eyes and mouth. The trial ran at more than one site and assigned patients by chance to one of two drugs. One group took iguratimod and the other took a drug in wide use, each for 24 weeks.
Seventy-eight patients joined, and sixty-six finished the trial. The main score trended higher with iguratimod but did not reach a clear gap. Two key scores and a blood protein measure did improve more with the drug. Side effects were more common with it, though most were mild. The team sees it as a hopeful choice.
Catalog record
| CREATOR | Xiaochan Chen, Ting Zhang, Lifeng Meng, Cheng Xu, Lichun Jiang, Guofang Wang, Tao Hou, Hongzhi Wang, Yongmei Han, Ying Guan, Yingying Wang, Jing Xue |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |